Renoprotective Effect of Vasopressin V2 Receptor Antagonist Tolvaptan in Dahl Rats With End-Stage Heart Failure-Reference-Cited by-同舟云学术

Renoprotective Effect of Vasopressin V2 Receptor Antagonist Tolvaptan in Dahl Rats With End-Stage Heart Failure

Published:2013 Issue:2 Volume:54 Page:98-106
ISSN:1349-2365
Container-title:International Heart Journal
language:en
Short-container-title:Int. Heart J.

Author:

Ishikawa Mayuko¹,Kobayashi Naohiko¹,Sugiyama Fumihiro¹,Onoda Sho¹,Ishimitsu Toshihiko¹

Affiliation:

1. Department of Cardiology and Nephrology, Dokkyo Medical University School of Medicine

Publisher

International Heart Journal (Japanese Heart Journal)

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/ihj/54/2/54_98/_pdf

Reference29 articles.

1. 1. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-9.

2. 2. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-22. (Review)

3. 3. Sebe A, Leivonen SK, Fintha A, et al. Transforming growth factor-beta-induced alpha-smooth muscle cell actin expression in renal proximal tubular cells is regulated by p38beta mitogen-activated protein kinase, extracellular signal-regulated protein kinase1,2 and the Smad signalling during epithelial-myofibroblast transdifferentiation. Nephrol Dial Transplant 2008; 23: 1537-45.

4. 4. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9: 964-8.

5. 5. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frøkiaer J, Marples D. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10: 647-63. (Review)

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kidney-tonifying blood-activating decoction delays ventricular remodeling in rats with chronic heart failure by regulating gut microbiota and metabolites and p38 mitogen-activated protein kinase/p65 nuclear factor kappa-B/aquaporin-4 signaling pathway;Journal of Ethnopharmacology;2024-08

2. Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice;European Journal of Histochemistry;2022-11-11

3. Potential Protective Effects of Antioxidants against Cyclophosphamide-Induced Nephrotoxicity;International Journal of Nephrology;2022-04-16

4. Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach;Journal of Clinical Medicine;2022-01-13

5. Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia;ESC Heart Failure;2021-09-23